205 related articles for article (PubMed ID: 23757319)
21. Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C.
Bares JM; Berger J; Nelson JE; Messner DJ; Schildt S; Standish LJ; Kowdley KV
J Clin Gastroenterol; 2008 Sep; 42(8):937-44. PubMed ID: 18458640
[TBL] [Abstract][Full Text] [Related]
22. Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma.
Goyal L; Supko JG; Berlin J; Blaszkowsky LS; Carpenter A; Heuman DM; Hilderbrand SL; Stuart KE; Cotler S; Senzer NN; Chan E; Berg CL; Clark JW; Hezel AF; Ryan DP; Zhu AX
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1305-14. PubMed ID: 24121453
[TBL] [Abstract][Full Text] [Related]
23. Toxicology and carcinogenesis studies of milk thistle extract (CAS No. 84604-20-6) in F344/N rats and B6C3F1 mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2011 May; (565):1-177. PubMed ID: 21685957
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
25. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.
Fried MW; Navarro VJ; Afdhal N; Belle SH; Wahed AS; Hawke RL; Doo E; Meyers CM; Reddy KR;
JAMA; 2012 Jul; 308(3):274-82. PubMed ID: 22797645
[TBL] [Abstract][Full Text] [Related]
26. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.
Zhu AX; Gold PJ; El-Khoueiry AB; Abrams TA; Morikawa H; Ohishi N; Ohtomo T; Philip PA
Clin Cancer Res; 2013 Feb; 19(4):920-8. PubMed ID: 23362325
[TBL] [Abstract][Full Text] [Related]
27. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
[TBL] [Abstract][Full Text] [Related]
28. Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases.
Abenavoli L; Izzo AA; Milić N; Cicala C; Santini A; Capasso R
Phytother Res; 2018 Nov; 32(11):2202-2213. PubMed ID: 30080294
[TBL] [Abstract][Full Text] [Related]
29. Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin.
Bosch-Barrera J; Sais E; Cañete N; Marruecos J; Cuyàs E; Izquierdo A; Porta R; Haro M; Brunet J; Pedraza S; Menendez JA
Oncotarget; 2016 May; 7(22):32006-14. PubMed ID: 26959886
[TBL] [Abstract][Full Text] [Related]
30. Silibinin Improves TNF-α and M30 Expression and Histological Parameters in Rat Kidneys After Hepatic Ischemia/Reperfusion.
Kyriakopoulos G; Tsaroucha AK; Valsami G; Lambropoulou M; Kostomitsopoulos N; Christodoulou E; Kakazanis Z; Anagnostopoulos C; Tsalikidis C; Simopoulos CE
J Invest Surg; 2018 Jun; 31(3):201-209. PubMed ID: 28418711
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and safety of silibinin in horses.
Hackett ES; Mama KR; Twedt DC; Gustafson DL
Am J Vet Res; 2013 Oct; 74(10):1327-32. PubMed ID: 24066917
[TBL] [Abstract][Full Text] [Related]
32. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences.
Hoh C; Boocock D; Marczylo T; Singh R; Berry DP; Dennison AR; Hemingway D; Miller A; West K; Euden S; Garcea G; Farmer PB; Steward WP; Gescher AJ
Clin Cancer Res; 2006 May; 12(9):2944-50. PubMed ID: 16675592
[TBL] [Abstract][Full Text] [Related]
33. Silybin and the liver: from basic research to clinical practice.
Loguercio C; Festi D
World J Gastroenterol; 2011 May; 17(18):2288-301. PubMed ID: 21633595
[TBL] [Abstract][Full Text] [Related]
34. An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma.
El Dika I; Lim HY; Yong WP; Lin CC; Yoon JH; Modiano M; Freilich B; Choi HJ; Chao TY; Kelley RK; Brown J; Knox J; Ryoo BY; Yau T; Abou-Alfa GK
Oncologist; 2019 Jun; 24(6):747-e218. PubMed ID: 30598500
[TBL] [Abstract][Full Text] [Related]
35. Effects and mechanisms of silibinin on human hepatoma cell lines.
Lah JJ; Cui W; Hu KQ
World J Gastroenterol; 2007 Oct; 13(40):5299-305. PubMed ID: 17879397
[TBL] [Abstract][Full Text] [Related]
36. Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.
Schrieber SJ; Hawke RL; Wen Z; Smith PC; Reddy KR; Wahed AS; Belle SH; Afdhal NH; Navarro VJ; Meyers CM; Doo E; Fried MW
Drug Metab Dispos; 2011 Dec; 39(12):2182-90. PubMed ID: 21865319
[TBL] [Abstract][Full Text] [Related]
37. Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Shahda S; Loehrer PJ; Clark RS; Spittler AJ; Althouse SK; Chiorean EG
Oncologist; 2016 Jun; 21(6):664-5. PubMed ID: 27256874
[TBL] [Abstract][Full Text] [Related]
38. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
39. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.
El-Khoueiry AB; O'Donnell R; Semrad TJ; Mack P; Blanchard S; Bahary N; Jiang Y; Yen Y; Wright J; Chen H; Lenz HJ; Gandara DR
Cancer Chemother Pharmacol; 2018 May; 81(5):957-963. PubMed ID: 29520435
[TBL] [Abstract][Full Text] [Related]
40. Development of a HPLC-UV assay for silybin-phosphatidylcholine complex (silybinin capsules) and its pharmacokinetic study in healthy male Chinese volunteers.
Li W; Gao J; Zhao HZ; Liu CX
Eur J Drug Metab Pharmacokinet; 2006; 31(4):265-70. PubMed ID: 17315537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
